MAP2K7 and neoplasm: In this study we further characterized the 13C-metabolic profile in response to BRAF/MEK targeted therapies in YUMM1.7 syngeneic melanoma xenografts characterized for BrafV600E/wt Pten−/− Cdkn2−/−, allowing the use of immunocompetent mice to fully integrate all aspects of the tumor microenvironment.